Anumana Receives U.S. FDA Breakthrough Device Designation for its Cardiac Amyloidosis Algorithm
Related Articles
Mayo-developed AI detects heart condition from Apple Watch ECGs
Modern Healthcare: An artificial-intelligence algorithm developed at Mayo Clinic could identify left ventricular dysfunction—or a weak heart pump—in most patients based on Apple Watch data, researchers shared at a conference…April 30, 2022
Trial demonstrates early AI-guided detection of heart disease in routine practice
Medical Xpress: Heart disease can take a number of forms, but some types of heart disease, such as asymptomatic low ejection fraction, can be hard to recognize, especially in the…May 15, 2021
Single-Lead ECG Tracings from an Apple Watch Effectively Identifies Patients with a Weak Heart Pump
AZO Robotics: Patients with a weak heart pump were identified using single-lead ECG tracings from an Apple Watch interpreted by an artificial intelligence (AI) algorithm developed at Mayo Clinic. Researchers…May 01, 2022
FDA grants breakthrough designation for Anumana’s ECG-AI algorithm
Medical Device Network: The US Food and Drug Administration (FDA) has granted breakthrough device designation (BDD) for the electrocardiogram-artificial intelligence (ECG-AI) algorithm by AI-driven health technology company Anumana. The algorithm…June 22, 2023